Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2026 16:02 ET | Source: Kyntra Bio

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and...